Safety Evaluation of the KLOX BioPhotonic System in Stage II and III Pressure Ulcers (NCT02222454) | Clinical Trial Compass
CompletedNot Applicable
Safety Evaluation of the KLOX BioPhotonic System in Stage II and III Pressure Ulcers
Canada3 participantsStarted 2012-11
Plain-language summary
The primary objective of these case series is to evaluate the safety and tolerability of the KLOX BioPhotonic System as adjunctive therapy to Standard Of Care (SOC) in patients with stage II or III pressure ulcers.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male or female 18 years of age and older;
* The subject or legal guardian must have signed an informed consent form;
* Female of child bearing potential must have a negative pregnancy test result at Baseline and both male and female patients must be willing to adhere to a medically-accepted birth control method during the course of the study;
* Willingness to return for all study visits;
* Stage II or III pressure ulcer (as per NPUAP Staging Guidelines), present for more than 4 weeks (up to Screening visit), located in the ischial, trochanteric, coccygeal, thoracic or abdominal regions. Lower extremity pressure ulcers, such as heel ulcers, are acceptable provided that diabetic foot ulcers are ruled out if the patient has diabetes. Surface dimensions of ulcer must be between 2 to 64 cm2 inclusive but longest diameter must not exceed 10 cm. Depth must not exceed 5 cm;
* Wound area has not changed by more than +/- 30% between Screening visit and Week 1/Visit 1 (before treatment).
Exclusion Criteria:
* Pressure ulcer present for more than 18 months;
* The ulcer to be treated is planned for operative debridement;
* The ulcer has significant necrotic tissue (e.g., more than 20% of the ulcer area);
* Major uncontrolled medical disorder(s) such as serious cardiovascular, renal, liver or pulmonary disease, lupus, palliative care or sickle cell anemia;
* Severe or significant hypoalbuminemia (albuminemia \< 30 g/L, and/or pre-albumin \< 5 mg/dL), or hypoprotein…
What they're measuring
1
Safety and tolerability of the KLOX BioPhotonic System in patients with stage II or III pressure ulcers.